Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

Hier gibts nur einer Richtung! Sollten wir nochmal zum Luftholen auf die 120 gehen dann kauf ich gleich nach.

Wow. Woher ahnten sie das?

die Leute brauchen Geld fürs lange WE 😀

Achtung!

Die kritische Linie 120 ...

Klassische Gewinnmitnahmen am Freitag?

Dit jeht mir jetzt schon wieder zu sehr gen Süden hier.

Hat aber lt. Reuters keine Auswirkungen auf die laufende Produktion.

Bei Novo in Kalundborg ist ein Großbrand ausgebrochen, alle Mitarbeiter wurden evakuiert.

… schon gelesen? https://www.n-tv.de/wissen/Abnehmspritzen-senken-Risiken-fuer-Herzinfarkt-und-Schlaganfall-article24939769.html … und klar, schon dadurch, dass man dann weniger wiegt, sinkt das Risiko.

Inhalte, für die gezahlt werden müssen.

"payed content"??

... wenn wir hier die 114€ hinter uns gelassen haben, denke ich auch mal über payed content nach. Aber sieht ja ganz gut aus.

Leider ein Bezahl-Artikel, aber trotzdem von der Headline interessant. https://www.tagesspiegel.de/wissen/grosse-uberraschung-in-der-medizin-uber-die-unerwartete-nebenwirkung-von-ozempic-wegovy-und-co-11637074.html Bald steigen sie noch ins Geschäft um die Schwangerschaft ein 😀 ...

@seeb Delfin Can t imagine for just 1.2 million affected NN will spend huge amount for developping.Those in need just to small. Did I get something wrong ?

About Haemophilia Haemophilia is a rare inherited bleeding disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. It is estimated to affect approximately 1,125,000 people worldwide, and haemophilia A is estimated to account for 80-85% of all haemophilia cases. Due to the nature of haemophilia being a rare x-linked recessive disorder, it often presents differently in males compared to females, with ~ 88% of people diagnosed with haemophilia worldwide being male. There are different types of haemophilia, which are characterised by the type of clotting factor protein that is defective or missing. Haemophilia A is caused by a missing or defective clotting Factor VIII (FVIII). Some people with haemophilia may also develop inhibitors, which are an immune system response to the clotting factors in replacement therapy that cause treatment to stop working. Currently, it is estimated that up to 30% of people living with haemophilia A have inhibitors. About Mim8 Mim8 is a next-generation FVIIIa mimetic bispecific antibody delivering sustained haemostasis for once-weekly or once-monthly prophylaxis for people living with haemophilia A, with and without inhibitors. Administered subcutaneously, Mim8 bridges Factor IXa/X (FIXa/FX) together upon activation, thereby replacing missing FVIII, which effectively restores the body’s thrombin generation capacity, helping blood to clot. About the FRONTIER Programme The FRONTIER clinical development programme investigates Mim8 as a preventative treatment for people with haemophilia A, with or without inhibitors. The phase 3 programme includes: FRONTIER 2 – a 52-week efficacy and safety phase 3 trial, with a 26-52-week run-in period comparing once-weekly and once-monthly Mim8 versus no prophylaxis, and versus prior coagulation factor prophylaxis treatment prior to enrolment in people aged 12 years and over with haemophilia A, with or without inhibitors. Following the completion of the 26-week main phase of the trial, a 26-week extension phase is ongoing. FRONTIER 3 – a 52-week safety and efficacy phase 3 trial in paediatric patients with haemophilia A, with or without inhibitors (1-11 years). People will receive once-weekly Mim8 during the first 26 weeks and may subsequently choose to receive once-monthly Mim8. FRONTIER 4 – an open-label extension following participation in the FRONTIER phase 2 and phase 3 studies. The study allows the collection of long-term safety data. FRONTIER 5 – a 26-week phase 3 trial investigating pharmacokinetics, pharmacodynamics and safety of switching from previous emizicumab to Mim8 in adults and adolescents with haemophilia A, with or without inhibitors.